H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on COMPASS Pathways today and set a price target of $40.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Trucchio has given his Buy rating due to a combination of factors including the positive clinical trial results and strategic advancements by COMPASS Pathways. The Phase 3 COMP005 trial demonstrated significant efficacy with a single dose of COMP360, achieving a meaningful reduction in depression symptoms as measured by the Montgomery–Åsberg Depression Rating Scale. This establishes a strong foundation for regulatory approval, and ongoing discussions with the FDA are exploring accelerated pathways for the drug’s approval.
Furthermore, the company is making strides in commercial readiness for treatment-resistant depression, with a favorable reimbursement framework and a growing network of providers. COMP360’s treatment model, requiring fewer administrations compared to alternatives, presents a more practical option for patients and clinicians. The infrastructure for delivering COMP360 is well-established, with collaborations in place to address operational challenges, positioning the company for successful market entry. These factors collectively support the Buy rating and the optimistic outlook for COMPASS Pathways’ stock.